Market Updates

Recent Financing Allows WellGen to Begin Studies

Recent Financing Allows WellGen to Begin Studies
WellGen, Inc., New Brunswick, NJ, has completed its Series B financing totaling $3 million. The capital raised from this latest round of financing will provide the company with the additional resources it needs to begin clinical studies in humans under its Obesity and Inflammation Programs, which are aimed at developing and bringing to market a variety of new and promising nutritional products. Investors in this round of financing include both new and existing WellGen shareholders.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters